Drug Discovery 아웃소싱 시장 : 규모, 점유율, 동향 분석, 워크플로우별, 의약품별, 서비스별, 치료 영역별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 17.11 billion by 2033 and is expected to expand at a CAGR of 9.83% from 2025 to 2033, according to a new report by Grand View Research, Inc. The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

• The global market is expected to witness rising growth over the estimated time, fueled by the increasing complexity of therapeutic targets, rising research and development costs, and a growing pipeline of biotech companies with limited internal resources.
• The drug discovery outsourcing industry utilizes various pricing models for project complexity, risk-sharing arrangements, and client needs.
• In 2024, the lead identification and candidate optimization segment held the largest revenue share in the market based on the workflow segment.
• Based on the drug type segment, the small molecules segment accounted for the largest share in 2024 during the forecast period.
• Based on service segment, the market is segmented into chemistry services and biology services.
• Based on the therapeutics area segment, the respiratory system segment accounted for the largest market share in 2024.
• Based on the end use segment, the pharmaceutical & biotechnology companies segment accounted for the largest market share in 2024.
• In 2024, North America held the largest revenue share of 41.16% globally.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Workflow
  • 1.2.2. Drug
  • 1.2.3. Service
  • 1.2.4. Therapeutics Area
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing R&D In the Biopharmaceutical Industry
    • 3.2.1.2. Increasing demand for outsourcing Services in Drug Development
    • 3.2.1.3. Increasing number of partnerships in drug discovery research
    • 3.2.1.4. Technological advancements in drug discovery
    • 3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of open-source software packages for drug discovery
    • 3.2.2.2. High manufacturing costs coupled with a high risk of drug failure
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

• 4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
• 4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
• 4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2021 - 2033 (USD Million)
• 4.4. Target Identification & Screening
  • 4.4.1. Target Identification & Screening Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Target Validation & Functional Informatics
  • 4.5.1. Target Validation & Functional Informatics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Lead Identification & Candidate Optimization
  • 4.6.1. Lead Identification & Candidate Optimization Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Preclinical Development
  • 4.7.1. Preclinical Development Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Others
  • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Drug Discovery Outsourcing Market: Drug Estimates & Trend Analysis

• 5.1. Drug Discovery Outsourcing Market, By Drug: Segment Dashboard
• 5.2. Drug Discovery Outsourcing Market, By Drug: Movement Analysis
• 5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug, 2021 - 2033 (USD Million)
• 5.4. Small Molecules
  • 5.4.1. Small Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Large Molecules
  • 5.5.1. Large Molecules Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Drug Discovery Outsourcing Market: Service Estimates & Trend Analysis

• 6.1. Drug Discovery Outsourcing Market, By Service: Segment Dashboard
• 6.2. Drug Discovery Outsourcing Market, By Service: Movement Analysis
• 6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 6.4. Chemistry Services
  • 6.4.1. Chemistry Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biology Services
  • 6.5.1. Biology Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

• 7.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
• 7.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
• 7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics Area, 2021 - 2033 (USD Million)
• 7.4. Respiratory system
  • 7.4.1. Respiratory System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Pain and Anesthesia
  • 7.5.1. Pain and Anesthesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Oncology
  • 7.6.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Ophthalmology
  • 7.7.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Hematology
  • 7.8.1. Hematology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Cardiovascular
  • 7.9.1. Cardiovascular Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Endocrine
  • 7.10.1. Endocrine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.11. Gastrointestinal
  • 7.11.1. Gastrointestinal Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.12. Immunomodulation
  • 7.12.1. Immunomodulation Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.13. Anti-infective
  • 7.13.1. Anti-infective Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.14. Central Nervous System
  • 7.14.1. Central Nervous System Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.15. Dermatology
  • 7.15.1. Dermatology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.16. Genitourinary System
  • 7.16.1. Genitourinary System Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

• 8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
• 8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
• 8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million)
• 8.4. Pharmaceutical & Biotechnology companies
  • 8.4.1. Pharmaceutical & Biotechnology companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Academic Institutes
  • 8.5.1. Academic Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Dashboard
• 9.2. Regional Market Share Analysis, 2024 & 2033
• 9.3. North America
  • 9.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.2. U.S
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.3. Canada
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.3.4. Mexico
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.4. Europe
  • 9.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.2. UK
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.3. Germany
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.4. France
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.5. Italy
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.6. Spain
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.7. Denmark
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.8. Sweden
    • 9.4.8.1. Key Country Dynamics
    • 9.4.8.2. Competitive Scenario
    • 9.4.8.3. Regulatory Framework
    • 9.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.4.9. Norway
    • 9.4.9.1. Key Country Dynamics
    • 9.4.9.2. Competitive Scenario
    • 9.4.9.3. Regulatory Framework
    • 9.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.2. Japan
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.3. China
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.4. India
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Competitive Scenario
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.5. Thailand
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Competitive Scenario
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.6. South Korea
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Competitive Scenario
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5.7. Australia
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Competitive Scenario
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.6. Latin America
  • 9.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.2. Brazil
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6.3. Argentina
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 9.7. MEA
  • 9.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.2. South Africa
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Competitive Scenario
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.3. Saudi Arabia
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Competitive Scenario
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.4. UAE
    • 9.7.4.1. Key Country Dynamics
    • 9.7.4.2. Competitive Scenario
    • 9.7.4.3. Regulatory Framework
    • 9.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7.5. Kuwait
    • 9.7.5.1. Key Country Dynamics
    • 9.7.5.2. Competitive Scenario
    • 9.7.5.3. Regulatory Framework
    • 9.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Company Market Share/Assessment Analysis, 2024
• 10.3. Company Profiles
  • 10.3.1. Albany Molecular Research Inc.
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Financial Performance
    • 10.3.1.3. Service Benchmarking
    • 10.3.1.4. Strategic Initiatives
  • 10.3.2. EVOTEC
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Financial Performance
    • 10.3.2.3. Service Benchmarking
    • 10.3.2.4. Strategic Initiatives
  • 10.3.3. Laboratory Corporation of America Holdings
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Performance
    • 10.3.3.3. Service Benchmarking
    • 10.3.3.4. Strategic Initiatives
  • 10.3.4. GenScript
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Performance
    • 10.3.4.3. Service Benchmarking
    • 10.3.4.4. Strategic Initiatives
  • 10.3.5. Charles River Laboratories
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Performance
    • 10.3.5.3. Service Benchmarking
    • 10.3.5.4. Strategic Initiatives
  • 10.3.6. WuXi AppTec
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Financial Performance
    • 10.3.6.3. Service Benchmarking
    • 10.3.6.4. Strategic Initiatives
  • 10.3.7. Thermo Fisher Scientific Inc.
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Financial Performance
    • 10.3.7.3. Service Benchmarking
    • 10.3.7.4. Strategic Initiatives
  • 10.3.8. Dalton Pharma Services
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Performance
    • 10.3.8.3. Service Benchmarking
    • 10.3.8.4. Strategic Initiatives
  • 10.3.9. Oncodesign
    • 10.3.9.1. Company Overview
    • 10.3.9.2. Financial Performance
    • 10.3.9.3. Service Benchmarking
    • 10.3.9.4. Strategic Initiatives
  • 10.3.10. Jubilant Biosys
    • 10.3.10.1. Company Overview
    • 10.3.10.2. Financial Performance
    • 10.3.10.3. Service Benchmarking
    • 10.3.10.4. Strategic Initiatives
  • 10.3.11. DiscoverX Corp.
    • 10.3.11.1. Company Overview
    • 10.3.11.2. Financial Performance
    • 10.3.11.3. Service Benchmarking
    • 10.3.11.4. Strategic Initiatives
  • 10.3.12. QIAGEN
    • 10.3.12.1. Company Overview
    • 10.3.12.2. Financial Performance
    • 10.3.12.3. Service Benchmarking
    • 10.3.12.4. Strategic Initiatives
  • 10.3.13. Eurofins SE
    • 10.3.13.1. Company Overview
    • 10.3.13.2. Financial Performance
    • 10.3.13.3. Service Benchmarking
    • 10.3.13.4. Strategic Initiatives
  • 10.3.14. Syngene International Limited
    • 10.3.14.1. Company Overview
    • 10.3.14.2. Financial Performance
    • 10.3.14.3. Service Benchmarking
    • 10.3.14.4. Strategic Initiatives
  • 10.3.15. Dr. Reddy Laboratories Ltd.
    • 10.3.15.1. Company Overview
    • 10.3.15.2. Financial Performance
    • 10.3.15.3. Service Benchmarking
    • 10.3.15.4. Strategic Initiatives
  • 10.3.16. Pharmaron Beijing Co., Ltd.
    • 10.3.16.1. Company Overview
    • 10.3.16.2. Financial Performance
    • 10.3.16.3. Service Benchmarking
    • 10.3.16.4. Strategic Initiatives
  • 10.3.17. TCG Lifesciences Pvt Ltd.
    • 10.3.17.1. Company Overview
    • 10.3.17.2. Financial Performance
    • 10.3.17.3. Service Benchmarking
    • 10.3.17.4. Strategic Initiatives
  • 10.3.18. Domainex Ltd.
    • 10.3.18.1. Company Overview
    • 10.3.18.2. Financial Performance
    • 10.3.18.3. Service Benchmarking
    • 10.3.18.4. Strategic Initiatives